Aurélie Veugeois
University of Paris
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Aurélie Veugeois.
The Journal of Thoracic and Cardiovascular Surgery | 2016
Nicolas Amabile; Konstantinos Zannis; Aurélie Veugeois; Christophe Caussin
From the Cardiology Department and Cardiac Surgery Department, Institut Mutualiste Montsouris, Paris, France. Disclosures: C.C. is a proctor for Medtronic. All other authors have nothing to disclose with regard to commercial support. Received for publication June 6, 2016; revisions received July 12, 2016; accepted for publication July 24, 2016. Address for reprints: Nicolas Amabile, MD, PhD, Department of Cardiology, Institut Mutualiste Montsouris, 42 Blvd Jourdan, 75014 Paris, France (E-mail: [email protected]). J Thorac Cardiovasc Surg 2016;-:1-3 0022-5223/
Jacc-cardiovascular Interventions | 2016
Nicolas Amabile; Aurélie Veugeois; Jean-François Paul; Christophe Caussin
36.00 Copyright 2016 by The American Association for Thoracic Surgery http://dx.doi.org/10.1016/j.jtcvs.2016.07.079
Canadian Journal of Cardiology | 2017
Guy Achkouty; Nicolas Amabile; Konstantinos Zannis; Aurélie Veugeois; Christophe Caussin
An 81-year-old woman was referred to our center for severe aortic regurgitation (AR) related to bioprosthesis degeneration. She initially had an ascending aortic aneurysm with symptomatic AR and underwent surgical implantation of a Trifecta 21-mm prosthesis (St. Jude Medical, St. Paul, Minnesota),
European Heart Journal | 2016
Nicolas Amabile; Aurélie Veugeois; Konstantinos Zannis; Christophe Caussin
From January 2013 to January 2017, 686 consecutive patients were referred to our centre for transcatheter aortic valve replacement, including 5 subjects with severe aortic regurgitation and acute refractory cardiogenic shock. These patients were contraindicated for surgical treatment by the heart team because of high surgical risk (median logistic EuroSCORE: 74.6/Society of Thoracic Surgeons score: 37.9). The success rate of valve implantation was 100% through transfemoral access with self-expandable devices. The observed 30-day mortality rate was 20%. Hence, the transcatheter aortic valve replacement procedure might represent a successful and life-saving intervention for treatment of patients with severe aortic regurgitation who present with acute refractory cardiogenic shock.
Archives of Cardiovascular Diseases Supplements | 2016
Bahaa Alhabil; Christophe Caussin; Alain Dibie; Nicolas Amabile; Aurélie Veugeois; Luc H. Drieu; François Philippe
A 53-year-old man with a previous history of mediastinal radiotherapy was referred to our institution for coronary artery bypass graft and aortic valve replacement. Per-operative surgical analysis revealed poor flow within left and right internal mammary arteries (LIMA and RIMA), making their use as peducunlated conduits unsuitable. The proximal end arteries were removed and both vessels were harvested as free grafts. …
Archives of Cardiovascular Diseases Supplements | 2016
Bahaa Alhabil; Christophe Caussin; Alain Dibie; Nicolas Amabile; Aurélie Veugeois; Luc H. Drieu; Zoheir Mami; François Philippe
Background Paravalvular aortic regurgitation (PAR) after TAVR has been associated with increased mortality. The Sapien 3 device (Edwards Life-sciences) is different than the prior devices released by the same manufacturer in that it has a skirt designed to prevent paravalvular leak, improved coaxial alignment, and more accurate positioning. Aims To evaluate paravalvular aortic regurgitations after 30-day after TAVI using the Edwards SAPIEN 3 prosthesis. Methods Prospective monocentric study including 66 high-risk or non-operable patients with severe aortic stenosis undergoing TAVI using Edwards SAPIEN 3 prosthesis via transfemoral access, between September 2014 and March 2015. Results Mean age of patient was 84±7,1 years (70% female). The MDCT estimated an aortic annular diameter 25,07±2mm. Mean logistic EuroSCORE was 15,8±10,8. In our study, the device success rate was 98.5%. The pros-thesis has been deployed correctly in all cases and no failure of valve or embolization had occurred. Post TAVR, mean transaortic gradient decreased from 46,0±12,33mmHg to 8,2±3,37mmHg (p Conclusion In our study, TAVI with Edwards SAPIEN 3 demonstrated lower paravalvular aortic leak rates than earlier generation devices in patients at high risk for surgery.
International Journal of Cardiology | 2013
Barnabas Gellen; Pierre-François Lesault; Florence Canoui-Poitrine; Stéphane Champagne; Gauthier Mouillet; Dionyssis Pongas; Aurélie Le Thuaut; Tomislav Jakljevic; Sélim Boudiche; Marcos de la Vega; Abdelkader Maalej; Aurélie Veugeois; Jean-Luc Dubois-Randé; Emmanuel Teiger
Background Few data is available concerning the latest generation Edwards SAPIEN 3- S3 in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). Aims To evaluate periprocedural and 30-day clinical outcomes of TAVI using the Edwards SAPIEN 3 prosthesis) via transiliofemoral approach. Methods Between September 2014 and March 2015, consecutive high-risk or non-operable patients with severe aortic stenosis had TAVI using Edwards SAPIEN 3 prosthesis in Institut Mutualiste Montsouris. Valve Academic Research Consortium endpoints were used. Results Of 142 patients who underwent TAVI using Edwards SAPIEN prosthesis, 66 were treated with SAPIEN 3 via transfemoral access (mean age 84±7.1 years; 70% female). About 65% and 48% of patients had, respectively, severe peripheral artery diseases and calcified iliofemorale arteries. Multi-detector computed tomography estimated an aortic annular diameter of 25,07±2mm. Mean logistic EuroSCORE was 15,8±10,8. The device success rate was 98.5%. No failure of valve deployment had occurred and no patient had more than mild paravalvular aortic regurgitation. Mean transaortic gradient decreased from 46, 0±12,33mmHg to 8,2±3,37mmHg (p Conclusion In our study, TAVI with Edwards SAPIEN 3 was associated with a high rate of device success and low rate of paravalvular aortic regurgitations and major bleedings.
Canadian Journal of Cardiology | 2016
Vincent Spagnoli; Nicolas Amabile; Jean Guillaume Dillinger; Aurélie Veugeois; Damien Logeart; Patrick Henry; Christophe Caussin; Michel Slama
Canadian Journal of Cardiology | 2016
Julien Pascal; Aurélie Veugeois; Michel Slama; Saliah Rahal; Loic Belle; Christophe Caussin; Nicolas Amabile
International Journal of Cardiology | 2015
Sami Hammas; Aurélie Veugeois; Christophe Caussin; Nicolas Amabile